Phase 2 N=64 Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
Cystic Fibrosis · Lung Transplant
Primary: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Stable Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Recipients…
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
Phase 2 N=24 Effectiveness of Pulmozyme in Infants With Cystic Fibrosis
Cystic Fibrosis
Primary: Chest CT (High Resolution Computed Tomography (HRCT) Score) — 3.7; 6.1 Score points
Phase 3 N=238 Study of Ataluren (PTC124™) in Cystic Fibrosis
Cystic Fibrosis
Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264
Phase 2 N=151 Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
Cystic Fibrosis (CF)
Primary: Change in P. Aeruginosa Density — 0.23; -0.31; -0.31; -0.73 log10 CFU/g sputum — p=0.0014
N/A N=59 Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: The Number of Participants With Blood and Sputum Samples Collected — 18; 27; 0; 14 Participants
Phase 3 N=282 Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 90; 180 participants
Phase 4 N=982 Standardized Treatment of Pulmonary Exacerbations II
Pulmonary Cystic Fibrosis
Primary: Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day — 13.30; 13.83 percentage change — p=0.0164
N/A N=21 FDG-PET Imaging in Young Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Kinetic Influx Constant (Ki) — 0.009; 0.013 mL/min/mL
Phase 2 N=36 Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
Cystic Fibrosis
Primary: Change in Sputum Elastase Activity — -57 micrograms/mL
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
Phase 2 N=16 Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Cystic Fibrosis
Primary: Change in Mucociliary Clearance — 7.4; 9.5 percent clearance
Phase 3 N=330 MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Time to an Exacerbation — 58; 51.5 Days — p=0.0715
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
Phase 2 N=304 Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic Fibrosis · Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization — 24; 26; 29; 21 number of participants — p=0.86
N/A N=32 Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Lung Function: Lung Clearance Index — 9; 9.7 lung clearance index
N/A N=20 Intrapulmonary Percussive Ventilation for Sputum Induction in Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Sufficient Sputum Quantity for a Pellet — 9 Participants
N/A N=267 Early Intervention in Cystic Fibrosis Exacerbation
Cystic Fibrosis
Primary: Change in FEV1 — -0.07; -0.08 Liters
N/A N=22 Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Exercise Tolerance — 817; 792.22 meters
N/A N=31 Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
Cystic Fibrosis
Primary: Median Maximal Drug Concentration (Cmax) — 16.56; 12.5; 11.2; 3.0 mg/L
Phase 2 N=16 Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
Sinusitis · Cystic Fibrosis
Primary: Computed Tomography Evidence of Less Sinus Disease — 5.875; 3 units on a scale — p=0.2
Phase 2 N=8 CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
Cystic Fibrosis
Primary: Change in Sputum Bacterial Culture — -0.59; -0.89 CFU/mL
N/A N=402 Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
N/A N=21 Absorptive Clearance in the Cystic Fibrosis Airway
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Phase 4 N=11 Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
Cystic Fibrosis
Primary: Peak Plasma Concentration (Cmax) — 2.22; 2.92 mg/liter
N/A N=21 Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease
Cystic Fibrosis
Primary: Sputum White Cell Count — 6.93; 6.81 log 10 (cells/mL) — p=0.2772
Phase 3 N=191 Extension Study of Ataluren (PTC124) in Cystic Fibrosis
Cystic Fibrosis
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100; 97.9; 14.7; 18.8 percent of participants
Phase 2 N=14 Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
Cystic Fibrosis
Primary: 6 Minute Walk Distance — 25.2; 0.75 meters
Phase 2 N=8 Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
Cystic Fibrosis
Primary: Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging (3He-MRI) at Day 43 — -8.20 percentage of total…